LT2999714T - Surišančios molekulės, kurios suriša žmogaus komplemento faktorių c2 ir jų panaudojimas - Google Patents
Surišančios molekulės, kurios suriša žmogaus komplemento faktorių c2 ir jų panaudojimasInfo
- Publication number
- LT2999714T LT2999714T LTEP14729463.1T LT14729463T LT2999714T LT 2999714 T LT2999714 T LT 2999714T LT 14729463 T LT14729463 T LT 14729463T LT 2999714 T LT2999714 T LT 2999714T
- Authority
- LT
- Lithuania
- Prior art keywords
- binding molecules
- complement factor
- human complement
- bind human
- bind
- Prior art date
Links
- 230000000295 complement effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13168941 | 2013-05-23 | ||
| PCT/NL2014/050327 WO2014189378A1 (en) | 2013-05-23 | 2014-05-22 | Binding molecules that bind human complement factor c2 and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2999714T true LT2999714T (lt) | 2020-07-10 |
Family
ID=48485015
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP14729463.1T LT2999714T (lt) | 2013-05-23 | 2014-05-22 | Surišančios molekulės, kurios suriša žmogaus komplemento faktorių c2 ir jų panaudojimas |
| LTEP20165165.0T LT3725803T (lt) | 2013-05-23 | 2014-05-22 | Surišančios molekulės, kurios suriša žmogaus komplemento faktorių c2b, ir jų panaudojimas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP20165165.0T LT3725803T (lt) | 2013-05-23 | 2014-05-22 | Surišančios molekulės, kurios suriša žmogaus komplemento faktorių c2b, ir jų panaudojimas |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9944717B2 (enExample) |
| EP (2) | EP3725803B1 (enExample) |
| JP (3) | JP2016520313A (enExample) |
| CN (1) | CN105492461B (enExample) |
| AU (1) | AU2014269193C1 (enExample) |
| CA (1) | CA2913318C (enExample) |
| DK (2) | DK3725803T3 (enExample) |
| ES (2) | ES2904709T3 (enExample) |
| HU (2) | HUE049769T2 (enExample) |
| LT (2) | LT2999714T (enExample) |
| MX (1) | MX366046B (enExample) |
| PL (2) | PL3725803T3 (enExample) |
| PT (2) | PT3725803T (enExample) |
| WO (1) | WO2014189378A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS63212B1 (sr) | 2012-11-02 | 2022-06-30 | Bioverativ Usa Inc | Antikomplementna c1s antitela i njihove primene |
| DK3725803T3 (da) * | 2013-05-23 | 2022-03-07 | Broteio Pharma B V | Bindingsmolekyler som binder human komplementfaktor C2b, og anvendelser deraf |
| EP3525583B8 (en) | 2016-10-12 | 2025-09-10 | Bioverativ USA Inc. | Anti-c1s antibodies and methods of use thereof |
| FI3893924T3 (fi) * | 2018-12-13 | 2024-10-04 | argenx BV | Ihmisen komplementtitekijän C2B vasta-aineita sekä niiden käyttötapoja |
| GB2584105B (en) | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
| US20220332804A1 (en) * | 2019-08-12 | 2022-10-20 | Csl Innovation Pty Ltd. | Complement C2 Binding Proteins and Uses Thereof |
| EP4469475A1 (en) * | 2022-01-29 | 2024-12-04 | Kira Pharmaceuticals (Suzhou) Ltd. | Anti-c2 antibodies and uses thereof |
| GB202407051D0 (en) | 2024-05-17 | 2024-07-03 | argenx BV | Methods of treating osteoarthritis pain |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| ATE435873T1 (de) | 2000-03-23 | 2009-07-15 | Genentech Inc | Anti-c2/c2a inhibitoren zur komplement aktivierung |
| DK3725803T3 (da) | 2013-05-23 | 2022-03-07 | Broteio Pharma B V | Bindingsmolekyler som binder human komplementfaktor C2b, og anvendelser deraf |
-
2014
- 2014-05-22 DK DK20165165.0T patent/DK3725803T3/da active
- 2014-05-22 HU HUE14729463A patent/HUE049769T2/hu unknown
- 2014-05-22 PT PT201651650T patent/PT3725803T/pt unknown
- 2014-05-22 CN CN201480042146.0A patent/CN105492461B/zh active Active
- 2014-05-22 PL PL20165165T patent/PL3725803T3/pl unknown
- 2014-05-22 HU HUE20165165A patent/HUE057858T2/hu unknown
- 2014-05-22 AU AU2014269193A patent/AU2014269193C1/en active Active
- 2014-05-22 EP EP20165165.0A patent/EP3725803B1/en active Active
- 2014-05-22 PL PL14729463T patent/PL2999714T3/pl unknown
- 2014-05-22 LT LTEP14729463.1T patent/LT2999714T/lt unknown
- 2014-05-22 PT PT147294631T patent/PT2999714T/pt unknown
- 2014-05-22 EP EP14729463.1A patent/EP2999714B1/en active Active
- 2014-05-22 CA CA2913318A patent/CA2913318C/en active Active
- 2014-05-22 DK DK14729463.1T patent/DK2999714T3/da active
- 2014-05-22 ES ES20165165T patent/ES2904709T3/es active Active
- 2014-05-22 JP JP2016515304A patent/JP2016520313A/ja active Pending
- 2014-05-22 MX MX2015016120A patent/MX366046B/es active IP Right Grant
- 2014-05-22 US US14/892,850 patent/US9944717B2/en active Active
- 2014-05-22 ES ES14729463T patent/ES2784616T3/es active Active
- 2014-05-22 WO PCT/NL2014/050327 patent/WO2014189378A1/en not_active Ceased
- 2014-05-22 LT LTEP20165165.0T patent/LT3725803T/lt unknown
-
2018
- 2018-02-23 US US15/903,810 patent/US10717785B2/en active Active
-
2019
- 2019-08-13 JP JP2019148550A patent/JP7163254B2/ja active Active
-
2022
- 2022-10-19 JP JP2022167816A patent/JP7414929B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201505209B (en) | Binding molecules for bcma and cd3 | |
| IL254223A (en) | CD20 binding compounds and their uses | |
| IL240045A0 (en) | Antigen-binding molecules activate bi-specific t cells | |
| IL240838A0 (en) | Anti-3–lag binding proteins | |
| SG11201505762XA (en) | Il-11r binding proteins and uses thereof | |
| SG11201600275PA (en) | Novel adsorbent composition and use thereof | |
| ES3048528T3 (en) | Ligand binding molecules and uses thereof | |
| PL2999714T3 (pl) | Cząsteczki wiążące, które wiążą ludzki czynnik c2 dopełniacza oraz ich zastosowania | |
| SI3072905T1 (sl) | IL-17A-vezavno sredstvo in uporabe le-tega | |
| ZA201507808B (en) | Binding element | |
| GB201306588D0 (en) | Peptides and Binding Partners Therefor | |
| ZA201503962B (en) | Fines binding process and binding composition thereof | |
| HU4488U (en) | Plaster-coated and edge-protected chipboard | |
| GB201314294D0 (en) | Binding surfaces |